Direct-acting oral anticoagulant drug level monitoring in clinical patient management

The effect of bariatric surgery on direct-acting oral anticoagulant drug levels

(2018) Amihai Rottenstreich et al.   THROMBOSIS RESEARCH

Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay

(2017) Ling He et al.   THROMBOSIS RESEARCH

Evolving Treatments for Arterial and Venous Thrombosis

(2016) Noel C. Chan et al.   CIRCULATION RESEARCH

Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors

(2016) Jacob Beyer et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?

(2016) S. Desmaele et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF

(2016) Kevin E. Chan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

To measure or not to measure direct oral anticoagulants before surgery or invasive procedures

(2016) A. Tripodi   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study

(2016) S. Testa et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH

(2016) K. Martin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?

(2016) Sean G. Yates et al.   TRANSFUSION AND APHERESIS SCIENCE

Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients

(2016) Jean Amiral et al.   TRANSFUSION AND APHERESIS SCIENCE

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban

(2015) Charles E. Frost et al.   CLINICAL PHARMACOKINETICS

Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

(2015) Christian T Ruff et al.   LANCET

External Validity of the ARISTOTLE Trial in Real-Life Atrial Fibrillation Patients

(2014) Lovisa Hägg et al.   Cardiovascular Therapeutics

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

(2014) S. Halvorsen et al.   EUROPEAN HEART JOURNAL

The laboratory and the direct oral anticoagulants

(2013) A. Tripodi   BLOOD

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

(2013) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients

(2013) Paul A. Reilly et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

(2013) T. Baglin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate

(2013) Jean-Michel Dogné et al.   THROMBOSIS AND HAEMOSTASIS

Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban

(2013) Bernard Chatelain et al.   THROMBOSIS AND HAEMOSTASIS

Pros and cons of new oral anticoagulants

(2013) K. A. Bauer   Hematology-American Society of Hematology Education Program

Rivaroxaban

(2011) Wolfgang Mueck et al.   CLINICAL PHARMACOKINETICS

Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor

(2011) Richard C. Becker et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

(2008) Lars C. Borris et al.   THROMBOSIS AND HAEMOSTASIS